Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: The estimated annual prevalence of drug use disorders is as high as 3%, underpinning the need to continually develop more effective treatments. Central nervous system dysregulation, contributing to acute and post-withdrawal syndromes, has traditionally been managed with benzodiazepines; however, a small but growing body of data indicate that the GABA A receptor antagonist, flumazenil, may offer some advantages over traditional management. Aim: To review the literature on the safety and efficacy of flumazenil in benzodiazepine use disorders and identify gaps in the literature. Method: A systematic method was used to identify randomised control trials. Where randomised control trials existed, non-randomised control trials were included to supplement findings. Results: Eleven flumazenil trials were included with varying doses, frequencies and routes of administration. The evidence for flumazenil alone showed generally a reduction in withdrawal symptoms with the exception of one study where withdrawal symptoms initially increased. Flumazenil plus benzodiazepine tapering was assessed in one randomised control trial and a series of non-randomised control trials. Randomised control trial results showed that flumazenil plus benzodiazepine tapering was superior at reducing withdrawal symptoms compared to benzodiazepine tapering alone and placebo. Flumazenil was associated with no serious adverse events; however there remains a risk of seizures. Conclusion: Although flumazenil shows promising efficacy in the management of benzodiazepine use disorders and withdrawal, more randomized control trials are required before a definitive recommendation can be made around its use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
New findings on biological factors predicting addiction relapse vulnerability
Sinha, R. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0224-0 · Cited by 401 · cited 2×
“Despite the available therapies, studies have demonstrated that over two thirds of patients relapse within weeks to months of treatment initiation, and more than 80% relapse within one year (Brandon et al., 2007; Sinha, 2011), underpinning the need for continually developing more effective treatments.”
BackgroundRelapse and Relapse Prevention
Brandon, T. H., Vidrine, J. I., & Litvin, E. B. (2007) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.3.022806.091455 · Cited by 385 · cited 2×
“Despite the available therapies, studies have demonstrated that over two thirds of patients relapse within weeks to months of treatment initiation, and more than 80% relapse within one year (Brandon et al., 2007; Sinha, 2011), underpinning the need for continually developing more effective treatments.”
BackgroundNeuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160
Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002) · Addiction Biology · doi:10.1080/1355621021000005973 · Cited by 82 · cited 14×
“Two of the RCTs were not blinded to participants and personnel and were deemed high risk of performance bias (Gerra et al., 1993, 2002).”
BackgroundMethodInfluentialA controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users
Mintzer, M. Z., Stoller, K. B., & Griffiths, R. R. (1999) · Psychopharmacology · doi:10.1007/s002130051161 · Cited by 45
Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome
Ashton, H. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-11 · Cited by 32
Hulse, G., O’Neil, G., Morris, N., Bennett, K., Norman, A., & Hood, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112446532 · Cited by 27
Cited by
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
MacDonald, T., Gallo, A. T., Basso-Hulse, G., Bennett, K. S., & Hulse, G. K. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109501 · Cited by 12
Self-citationGallo, A., MacDonald, T., Bennett, K., Basso-Hulse, G., & Hulse, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195948 · Cited by 2
Self-citation
Metadata
- Authors
- Gallo, A. T., & Hulse, G.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-01-09
- Volume
- 35
- Issue
- 3
- Pages
- 211-220
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3118530976
- Cited by
- 28
- References
- 8
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. https://app.cochat.ai/papers/10.1177/0269881120981390
- The paper
- Gallo, A. T., & Hulse, G. (2021). Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. Journal of Psychopharmacology. https://doi.org/10.1177/0269881120981390
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.